# Repligen Is Betting the Next Big IP War in Biopharma Won’t Be About Molecules - Date: 2026-04-15 - Category: Biotech & Life Sciences Repligen took equity in Novasign in September 2025 before announcing the partnership in July. The order tells you where biopharma manufacturing IP is heading: away from molecules, toward process data. ---